ARDT

Ardent Health Partners, LLC (ARDT) Economic Moat Analysis (2026)

Invetso Score: 5.8/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Pricing Power

Gross margin is about 30.0%, indicating some pricing power but not a wide moat.

Price-to-sales of 0.24 suggests the market is still valuing the business as a low-multiple operator rather than a premium franchise.

Cost Advantage

Operating margin is 7.5%, showing decent cost discipline but not a structurally superior cost position.

SG&A at 15.9% of revenue and free cash flow conversion remain supportive of a modest efficiency edge.

Switching Costs

No direct evidence of high switching costs is visible in the financials, so this remains an inferred rather than proven moat factor.

Stable receivables and inventory turnover suggest normal customer retention and operating continuity, but not strong lock-in.

Network Effects

The financial data does not indicate clear network effects or self-reinforcing scale dynamics.

Revenue and cash flow metrics look steady, but there is no evidence of a platform-like flywheel.

Intangible Assets

Intangibles are 18.3% of total assets, implying some brand, contract, or acquired asset base but not a dominant moat.

There is no R&D intensity to suggest a strong innovation moat, so intangible strength appears limited.

Efficient Scale

The business appears to operate in a niche with reasonable capital efficiency, but the data does not prove an efficient-scale advantage.

Return on invested capital of 9.3% is respectable, yet not high enough to signal a clearly entrenched scale moat.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ardent Health Partners, LLC. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →